Richard T. Lee, M.D.
We don’t always have to think about a prescription as the first option. There’s a lot of things that we can do through mind-body approaches that have very few side effects but really profound effects on how patients feel. When we help them feel better or sleep better, they’ll have a lot less stress and it improves their quality of life. - Richard T. Lee, M.D.
2012, Hospice and Palliative Medicine
2008, Medical Oncology, American Board of Internal Medicine
2004, Internal Medicine, American Board of Internal Medicine
2001, Doctor of Medicine, George Washington University, Washington, DC, Maryland
1998, Bachelor of Arts, George Washington University, Washington, DC, Maryland
2008-2009, Palliative Medicine, Northwestern University, Chicago, IL
2006-2008, Medical Ethics, University of Chicago, Chicago, IL
2005-2008, Hematology/Oncology, University of Chicago, Chicago, IL
2004-2005, Fulbright Scholar, China Medical University Hospital, Taichung, Taiwan
- 2002-2004, Internal Medicine, Stanford University School of Medicine, Stanford, California
- 2001-2002, Internal Medicine, Stanford University School of Medicine, Stanford, California
2022-present, Medical Director, Integrative Medicine Program, Department of Supportive Care Medicine, City of Hope, Newport Beach Fashion Island, CA
2018-2022, Interim Medical Director, Palliative Care, University Hospitals Seidman Cancer Center
2015-2022, Medical Director, Supportive & Integrative Oncology Program, University Hospitals Seidman Cancer Center
2015-2022, Associate Professor, Palliative, Rehabilitation, and Integrative Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2014-2015, Assistant Professor, Department of Internal Medicine, The University of Texas Medical School at Houston, Houston, TX
2009-2015, Medical Director, Integrative Medicine Program, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2009-2015, Assistant Professor, Palliative, Rehabilitation and Integrative Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2018-2019, ASCO Leadership Development Program
2011-2015, Helen Moss Foundation-Schoff Family Professor of Integrative Oncology
2008-2009, Midwest Trainee Travel Award, Clinical Society for Clinical Research
2008, ASCO Foundation Merit Award, American Society of Clinical Oncology
2008, ASCO Cancer Foundation Young Investigator Awards, American Society of Clinical Oncology
2001, Doris Deford Speck Award, George Washington University Medical Center
1999, Lamport Award, George Washington University Medical Center
2017-present, Member, American Academy of Hospice and Palliative Medicine
2007-present, Member, Society for Integrative Oncology
2005-present, Member, American Society of Clinical Oncology
- Mangla A, Cioffi G, Patil N, Rothermel LD, Ammori JB, Barnholtz-Sloan JS, Lee RT. Surgical Resection for Primary Liver Angiosarcoma: National Cancer Database Analysis 2004-2014. ) Curr Oncol. 2022 May 17;29(5):3637-3646. PMID: 35621682
- Mohamed A, Asa SL, McCormick T, Al-Shakhshir H, Dasari A, Mauricio R, Salem I, Ocuin LM, Bajor D, Lee RT, Selfridge J, Arash J, Lee Z, Avril N, Kopp S, Winter JM, Hardacre JM, Ammori JB, Ghannoum MA. The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). Curr Issues Mol Biol. 2022 Apr 30;44(5):2015-2028. PMID: 35678665
- Huang LF*, Hong A*, Cioffi G, Alahmadi A*, Tang TY*, Ocuin LM, Patel N, Bajor DL, Saltzman JN, Mohamed A, Selfridge E, Hooper MW, Barnholtz-Sloan J, Lee RT. The Effect of Race on Adherence to NCCN Guidelines for Patients with High-Risk Biliary Tract Cancers After Surgery. Front Oncol. 2022 Feb 22;12:771688. PMID: 35273909
- Tang TY*, Daunov K*, Lee RT. Durable Response to Very Low Dose Sorafenib and Regorafenib in Advanced Hepatocellular Carcinoma. Front Oncol. 2021 Dec 16;11:780798. eCollection 2021.PMID:34976819
- Rodgers-Melnick SN, Zanotti K, Lee RT, Hooper WB. Demographic and Clinical Predictors of Engaging in Tobacco Cessation Counseling at a Comprehensive Cancer Center. JCO Oncol Pract. 2022 Jan 7: PMID: 34995104
- Sugumar K, Markt SC, Hue JJ, Hoehn RS, Lee RT, Chavin KD, Rothermel LD, Winter JM, Hardacre JM, Ammori JB, Ocuin LM.. Black race is independently associated with underutilization of transplantation for clinical T1 hepatocellular carcinoma. HPB (Oxford). 2021 Nov 6:S1365-182X(21)01690-7. PMID: 34872866
- Dans M, Kutner JS, Agarwal R, Baker JN, Bauman JR, Beck AC, Campbell TC, Carey EC, Case AA, Dalal S, Doberman DJ, Epstein AS, Fecher L, Jones J, Kapo J, Lee RT, Loggers ET, McCammon S, Mitchell W, Ogunseitan AB, Portman DG, Ramchandran K, Sutton L, Temel J, Teply ML, Terauchi SY, Thomas J, Walling AM, Zachariah F, Bergman MA, Ogba N, Campbell M. NCCN Guidelines® Insights: Palliative Care, Version 2.2021. J Natl Compr Canc Netw. 2021 Jul 28;19(7):780-788. PMID: 34340208
- Opneja A*, Cioffi G, Alahmadi A*, Patil P, Jones N, Tang T*, Bajor DL, Saltzman JN, Mohamed M, Mangla A, Barnholtz-Sloan J, Lee RT. The Adoption of Single Agent Chemotherapy for Advanced Hepatocellular Carcinoma and Impact of Facility Type, Insurance Status, and Income on Survival: Analysis of the National Cancer Database (NCDB) 2004-2014. Cancer Med 2021 May 31 PMID: 34060249
- Jurdi, NE, Nock N, Fu P, Cao S, Cotton JM, Ali N, Ravi R, Pinto R, Galloway E, Kolke S, Cooper B; Tomlinson B, Malek E, Lance C, Kolk MJ, Ferrari N, Lee RT, Lima M; Caimi PF. Physical Activity and Sleep Measures Using a Fitness Tracking Device during Hematopoietic Cell Transplantation: A Prospective Feasibility Study. Transplant Cell Ther. 2021 Feb 19:S2666-6367(21)00694-1 PMID:33827757
- Jiang C*, Larbi O*, Feyes D, Wang G, Momotaz H, Li M, Daunov K*, Daly B, Mazanec S, Rodgers-Melnick S, Rolfe S, Tamburro N, Hobson S, Lee RT. A survey of cancer patients, caregivers, and providers regarding familiarity, importance, and utilization of supportive and integrative oncology services. Support Care Cancer. 2021 Mar 19. PMID: 33740131
- Lee RT, Yang P, Alahmadi A*, McQuade J, Yuan E, Difeo A, Narla G, Kaseb A. Mistletoe Extract Viscum Fraxini-2 for Treatment of Advanced Hepatocellular Carcinoma: A Case Series. Case Rep Oncol 2021;14:224–231. PMID: 33776708
- Hlubocky FJ, Symington B, Gallagher C, Dragnev KH, Burke JB, Lee RT, El-Jawahri A, Popp B, Rosenberg A, Thompson M, Dizon D, Srivastava P, Patel M, Back AL, Daugherty CK, Kamal AH, McFarland DC, Dokucu M, Shanafelt T. The Impact of the COVID-19 Epidemic on Oncologist Burnout, Emotional Well-Being, & Moral Distress: Considerations for the Cancer Organization’s Ethical Response for Readiness, Resilience, & Mitigation. JCO Oncol Pract. 2021 Feb 8. PMID: 33555934
- Lee RT, Kwon N, Wu J, To C, To S, Szmulewitz R, Tchekmedyian R, Holmes H, Olopade OI, Stadler WM, Von Roenn J. Prevalence of potential medication interactions including herbs and supplements before, during, and after chemotherapy in breast and prostate cancer patients. Cancer. 2021 Feb 1. PMID: 33524183
- Larbi O*, Jiang C*, Bristol B, Wang G, Daunov K*, Hobson S, Daly B, Mazanec S, Feyes D, Rodgers-Melnick S , Momotaz H, Li M, Lee RT. Interest and Willingness to Pay for Integrative Therapies of Patients With Cancer and Caregivers. JCO Oncol Pract. 2021 Jan 22. PMID: 33492981
- Power-James C, Alvarez A*, Milbury K, Barbo A, Daunov K, Lopez G, Cohen L, Delgado-Guay M, Olopade OI, Lee RT. The influence of spirituality and religiosity on US oncologists’ personal use of and clinical practices regarding complementary and alternative medicine (CAM). Integr Cancer Therap. Integr Cancer Ther Jan-Dec 2020;19 PMID: 32830556